LONGEVETY CENTER
Welcome To Our Site
ExpertiesContact UsHow to stay youngTrainingBanefitsRejuvinate-regenerateMembership Fees



Experties

 

DR. Anand K. SHUKLA

 

M.B.B.S., Allahabad, U.P., M.D. (Pharma) Allahabad, U.P., Senior Resident – LHMC, Delhi, Diploma in Pharmacovigilance ICRI (New Delhi), Fellowship Clinical Research – Apollo Hospital, International Business Management Chennai.

 

1st Floor 6695/9 Payre Lal Road, Dev Nagar, Karol Bagh, New Delhi – 110005

Mobile: 9350228959
E-Mail:
dr_anandd@yahoo.com,

 

longevity.center@yahoo.com
Date of Birth: 15th June, 1961

 

 

 

 

Professor ,Pharmocovigilance Trainer Clinical Data Coordinator/Data Manager / Medical writer/ Clinical Research physician / Medical Advisor/ Clinical Research Associate / Co0Ordinator/ Project Manager / Programme Manager / Scientist with an organization of repute.


SYNOPSIS
                              

 

P.G Diploma in Pharmacovigilance & Fellowship in Clinical Research in Medical Practice & Clinical Research. Associated with Project –Longevity.

 

Hospital Management upto 200 beds. 

 

Proficiency in patient counseling and training subordinates in Protocol-based management of cases.

 

Managerial Skills

 

Possess Knowledge of:

 

Pharamcovigilance – Volume 9A, KDD, DATA Mining CIOMS, MedRA,

 

Pharmacogenomics

 

ICH-GCP, ICMR, DCGI, FDA & Schd. Y GUIDELINES.

 

IRBs, Investigator & CRA.

 

ICDs, CRFs, Ethics committee, SOPs and their contents.

 

AREAS OF EXPERTISE

 

Pharmacovigilance Interest:

 

a)     Played a major role in suspending a phase I trial due to suspected adverse events

 

b)     Pharmacovigilance approach in dose optimization for a drug tested for other therapeutic indications

 

c)     Pharmacovigilance strategy to overcome multidrug resistance in tuberculosis and to eliminate the same from Indian population

 

d)     Pharmaceutical approach towards Pharmacovigilance

 

e)     Pharmacovigilance approach towards Academia.

 

f)       Pharmacovigilance approach towards Medical Therapeutic.

 

g)     Pharmacovigilance approach towards Public Health.

 

h)     Pharmacovigilance Training for Health Professionals.

 

i)        Volume 9A- PSUR PADERS 

 

j)        Surveillance: Diseases and Pharmacovigilance – How Good are our Baseline Data?

 

 

a)     Safety Surveillance Plans: Strategies for Monitoring Safety during the Development Lifecycle

 

b)     Special Requirements for the Safety of Biologicals and Biosimilars

 

c)     Performance and Quality Control in Pharmacovigilance and Risk Management – Too Much or Too Little? What is the Impact on Public Health?

 

d)     EU-Harmonised Pharmacovigilance Requirements versus Global Pharmacovigilance – Supplement or Contradiction?

 

e)     Safety Decision Making – How much Science is Deployed? An update on Methodology

 

f)       Drug Safety Personnel – Which Qualification and How much Education is Needed? Where do Regulators and Industry Find Talent?

 

g)     Post-Marketing Studies – Commitments and Reality

 

h)     Safety Planning in Drug Development - Real Improvement or yet Another Document?

 

i)        Addressing Key Safety Challenges in Clinical Drug Development: Signal Detection and Continuous Risk Assessment

 

j)        Optimizing The Dilemma of the Informed Consent Process Between Ethical Requirements and Organisational Burden

 

k)     Communicating Benefit – Risk to the Public: 12 Years after the Erice Declaration, How much Progress Has Been Made?

 

l)        Safeguarding Public Health: Balancing Early Access with Safety and Affordability Aspects

 

m)   Benefit – Risk

 

n)     Key Initatives in Drug Development Optimisation

 

o)     Risk Management and Pharmacovigilance - Between a Regulatory Rock and the Litigation Hard Place

 

p)     New and Updated Regulations: How Do They Affect the Interface between Drugs and Devices?

 

q)     Medical Assessments and Safety-Evaluations for Medical Devices, Drugs and their Combinations

 

r)       Optimising The Dilemma of the Informed Consent Process Between Ethical Requirements and Organisational Burden

 

s)     Introduction of Biosimilar Medicines into Clinical PracticeAudits and Inspections on Pharmacovigilance

 

t)       Quality Risk Management and Risk Detection

 

 

 

MANAGERIAL SKILLS

 

 

  Clinical monitors and research associates

 

   Research & development scientists

 

   Medical and clinical investigators and study coordinators

 

    Physicians & medical liaisons

 

    Statisticians & data management professionals

 

    CMC/pharmaceutical research professionals

 

      Regulatory affairs professionals

 

    Project managers

 

     Brand team personnel

 

     Senior sales managers

 

    Strategic planners

 


 

Clinical Research

 

Organizing meetings with Clinical Investigators and staff prior to study initiation to ensure all aspects of the study are understood by the investigator & staff.

 

Confirming the appropriateness of the IRB & ensure that all documentation required to initiate the study is complete. Screening & assessing Clinical Trial Patient.

 

Leading a team of supervisor and field workers for carrying out protocol related activities.

 

Taking consent, writing drug chart, filling chemo format and blood form.

 

Diagnosing the disease & writing the prescription to the various patients under Sr. Consultant.

 

Writing & administration of Chemo therapy protocol.

 

Covered collection of all data & remaining study supplies for return to the Sponsor.

 

Adverse Event Monitoring & Reporting as per Protocol requirement.

 

Ensuring that screening and enrolled ID’s come to clinic in time.

 

Clinical examination at screening, enrollment and whenever required.

 

Ensuring that confidentiality and privacy of subjects is maintained.

 

Clinical Trial Patient screening, assessment, enrolment and follow up and its execution as per protocol.

 

Administering test article at timely intervals as per protocol.

 

Setting project goals, put strategic plan into practice,

 

Improving team quality and data quality by testing procedures,

 

Increasing productivity & efficiency of staff.

 

Accountable for medical care of subjects and ensuring that medicines reach to them.

 

Updating knowledge of GCP, ICMR guidelines.

 

Retraining field – workers how to ask about adverse events and filling of CRFs,

 

Training mothers how to make artificial feeds, breast feeds, reconstitution of medicines, observe child condition and informing AE team if condition worsens,

 

Refusal management in screening and enrollment by making field visit.

 

Optimizing use of organizational resources.

 

Managing communication. Providing senior management into what is happening & where things are going.

 

Meeting with Clinical Investigators and staff prior to study initiation to ensure all aspects of the study are understood by the investigator & staff, confirming the appropriateness of the IRB &

 

ensuring that all documentation required initiating the study is complete.

 

Monitoring study progress to assure compliance with protocol requirements, FDA regulations & Good Clinical Practice as directed by the Sponsor.

 

Monitoring & tracking patient enrollment & study progress. Ensuring the timely accurate & complete collection & submission of study data (CRF filling & checking updated)

 

Filling protocol deviation & filling CRFs promptly.

 

Identifying, addressing & resolving issues & problems as they might occur.

 

Error correction in CRFs as per GCP guidelines.

 

Ensuring collection of all data & remaining study supplies for reurn to the Sponsor,

 

Assisting the Sponsor in problem solving & provide consultation on study related activities.

 

 

 

Medical

 

Handling of casualty, seriously ill and dangerously ill patients.

 

Experience in History-taking, undertaking routine & diagnostic investigations & daily ward rounds.

 

Coordinating with the emergency team to ensure prompt response to emergencies.

 

Interfacing with specialists & multi-specialty units to ensure world-class standards of patient care.

 

Ensuring and monitoring administration of appropriate drugs to patients.

 

Handling patient counseling sessions,

 

Consent taking, drug chart writing, chemo format filling and blood form filling etc.

 

Filling adverse reaction form and managing the same.

 

 

 

RECENT MANAGEMENT IN PHARMACEUTICAL SAFETY 

  • Scientific Advice and the Transatlantic Simplification Process
  • Centralized procedure: New market authorization procedures and case studies
  • Update on Variation Regulations
  • Update on CMD(h) – Activities and the network
  • MRP / DCP procedures
  • Choice of RMS and availability of NCA resources
  • CMD(h) and CHMP referrals – interaction and case studies
  • Harmonization of SmPCs of national MA’s
  • The proposed new Pharmacovigilance Legislation
  • PSUR work-sharing and the link between PSURs and risk management plans
  • Transparency and public disclosure
  • Risk communication guideline
  • EudraCT and the impact of Paediatric Regulation
  • Risk management case studies
  • Telematics Roadmap and impact on regulatory business
  • Centralized procedure: eSubmission practicalities, Product

 

Information Management (PIM) and case studies

 

Drug Development Process – From Discovery to Commercialisation

 

 

  • Basic concepts of drug discovery and testing
  • Scientific, regulatory, and management framework for modern pharmaceutical development
  • Pre-clinical study requirements and how information gathered is used for human clinical studies
  • The four major clinical phases (1-4) in the drug development process and the rationale for each to the special problems of each phase
  • The economics of drug development
  • Cost/benefit issues in clinical development
  • Discovery and development milestones
  • The IND Process
  • The NDA Process
  • FDA Interactions – Application review and approval process
  • Patents and exclusivity
  • The rationale of government regulations and how they effect the development process
  • The relationship between the Code of Federal Regulations and ICH GCP
  • Designing optimal clinical trials
  • Drug labeling, marketing, and pharmacoeconomic studies
  • Project management cross functional teams during the development process.

 

ACADEMIC

 

 

 M.B.B.S 1986 Allahabad. U.P

 

 M.D  (Pharma) 1991 Allahabad. U.P

 

 Senior Resident - 1993-1997-LHMC. Delhi           

 

 Diploma in Pharmacovigilance ICRI- (New Delhi) Dec 2008

 

Fellowship Clinical  Research – Apollo Hospital. Dec 2008

 

International Business Management Chennai- 2003

 

 

 

TEACHING EXPERIENCE

 

 

Senior Resident – NMC, Model Town 1991-1993, Clinical Practice.

 

 Senior Resident – LHMC, New Delhi

 

Assistant Prof. – KIMS – 2005-2007

 

 Visiting Prof. – VMC, Pondichery. (Continued).

 

 Clinical  Practice and project in Longevity(Continued).  

 

 

 

 

ACCOLADES

 

 

Affiliate member of I.C.R., England

 

 Attended Clinical Research Seminar.

 

 Knowledge of Human Resource Management.

 

 Received an award for: Pharmacovigilance Symposium, Vishakapatnam.

 

Received an award for: Pharmacovigilance Symposium, SOPI, Jaipur.

 

 USFDA- Reviewer work regulation.

 

Chair person Poster judge in ITP- IPS Conferences, 2008, New Delhi AIIMS.

 

 Chair Person I.P.C., New Delhi, 2008   

 

Research Papers 

Disaster Management

 

Bio -terrorism

 

Pharmacovigilance – Vishakha Patnam Physiology &
Pharmacology

 

Pharmacovigilance \ SOPI- Jaipur

 

Electronic Work Management- Delhi School of Engineering

 

  Air Pollution & Health Check – Delhi 

 

Longevity – Modification of Physiology

 

Bio Informatics

 

Bioremediation

 

Medical Tourism

 

Pharmogenomics in Clinical Practice

 

 

Pharmogenomics & Pharmaceuticals &  Clinical Practice

 

Membership  Indian Science National Congress

 

Diabecon

 

Physiology & Pharmacology

 

Society of Pharmacology

 

Society of Pharmacovigilance India

 

Longevity Institute

 

DIA

 

Conference invited in 2008 Physiology & Pharmacology

 

DIA

 

IPS- AIIMS

 

IPC –Indian Pharmaceuticals Society

 

AIMS             

 

To make India aware of Pharmacovigilance for health Professional pharmaceuticals & public.

 

Develop other country for pharmacovigilance

 

To prepare  pharmacovigilance physician & Inspector’s.

 

NGO’s & BPO’s  Media & News Channels for Public Awareness of Drugs , adverse reaction reporting system & SOP. For IT solution.

 

References             

 

Professor DR. S.K. Gupta

 

Director General I.C.R.I.

 

Professor Dr. Y.K.Gupta

 

Director Head of A.I.I.M.S Phrama

 

 

Professor Dr. S. Minocha

 

Principal of C.R.E.M.A.

 

Professor Dr. Amit Verma

 

I.C.R.I. India


ExpertiesContact UsHow to stay youngTrainingBanefitsRejuvinate-regenerateMembership Fees